Results 181 to 190 of about 10,064 (258)

ITGA5 as a Dual Regulator of Epithelial‐Mesenchymal Transition and Epithelial Cell Anoikis Resistance: Functional Validation and Drug Prediction

Cell Proliferation, EarlyView.
Proteomics and functional validation reveal ITGA5 as a dual promoter of epithelial‐mesenchymal transition and anoikis resistance in human bronchial epithelium: targeting ITGA5 represents a novel therapeutic strategy for asthma airway remodelling. ABSTRACT Airway remodelling is a major contributor to persistent airflow limitation and irreversible lung ...
Ting Wang, Ling Rao, Xiaofang Li, Miaofen Zhang, Huiting Huang, Zhiyan Luo, Gang Liao, Yong Jiang, Shaofeng Zhan, Qiong Liu, Xiufang Huang   +10 more
wiley   +1 more source

Correction: Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs. [PDF]

J Nanobiotechnology
Zhao J, Ye H, Lu Q, Wang K, Chen X, Song J, Wang H, Lu Y, Cheng M, He Z, Zhai Y, Zhang H, Sun J.   +12 more
europepmc   +1 more source

Biopharmaceutic

Journal of Pharmacy and Pharmacology, 2006
openaire   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular‐kidney‐metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition.
Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S. Jhund, Paul R. Kalra, Hongtu Zhu, David C. Wheeler, Geraint Roberts, Martin R. Cowie, Andrew H. Briggs   +10 more
wiley   +1 more source

Evaluation of USP 3 Apparatus to Develop Biopredictive Fasted and Fed Dissolution Methods for Extended-Release Desvenlafaxine Succinate Tablets. [PDF]

ACS Omega
Carapeto GV, Nunes BC, Duque MD, Issa MG, Ferraz HG.   +4 more
europepmc   +1 more source

Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA). Aim Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec. Methods An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor
Priyanka Raheja, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Emily Symington, Carolyn Millar, Dane Osmond, Mingjin Li, Konstantia‐Maria Chavele   +9 more
wiley   +1 more source

Correction: Wu et al. Synthesis of Novel Lipophilic <i>N</i>-Substituted Norcantharimide Derivatives and Evaluation of Their Anticancer Activities. <i>Molecules</i> 2014, <i>19</i>, 6911-6928. [PDF]

Molecules
Wu JY, Kuo CD, Chu CY, Chen MS, Lin JH, Chen YJ, Liao HF.   +6 more
europepmc   +1 more source

Optimizing Perioperative Management of Haemophilia B With rFIX‐FP: Pharmacokinetic Validation of the Hemoptidose Tool

Haemophilia, EarlyView.
Abstract Background Surgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half‐life rFIX‐FP simplifies perioperative management but exhibits substantial pharmacokinetic variability.
Xavier Delavenne, Célia Vollard, Nicolas Drillaud, Sabine Castet, Nicolas Luyck, Emilie Hénin, Julien Denis‐Le Seve, Fabienne Volot, Brigitte Tardy, Stéphanie Désage, Benoît Guillet   +10 more
wiley   +1 more source

Albumin as a dynamic extracellular redox regulator: from Cys34 oxidation biomarkers to polysulfide-mediated homeostatic mechanisms and clinical applications. [PDF]

Redox Rep
Ishima Y, Watanabe H, Ikeda-Imafuku M, Maeda H, Maruyama T, Otagiri M, Chuang VTG.   +6 more
europepmc   +1 more source

Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This analysis used a large clinical trial data set (>30,000 patient visits across >2800 patients) and novel statistical methodologies (including frequency cross‐over analysis and means based on spline regression) to develop severity threshold bands for clinician‐ and patient‐reported outcome measures for adults with moderate‐to‐severe atopic dermatitis.
Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard   +7 more
wiley   +1 more source